Project Grant R01HL189540
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $648K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $660,671 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop microbiome-based therapy for treatment-refractory graft-versus-host disease. The project investigates the role of ileal microbiota in graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation. The research focuses on two mechanisms: insufficient suppression of alloreactive...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded The Johns Hopkins University $379,509 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop mesenchymal stem cell (MSC) therapies with enhanced immunosuppressive efficacy for graft-versus-host disease treatment through mechanical programming of cell microenvironments. The research focuses on identifying and providing optimal mechanical cues during MSC...
- The National Heart Lung and Blood Institute awarded Sloan-Kettering Institute For Cancer Research $281,722 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a rationally designed oral live biotherapeutic product (LBP) that delivers a defined composition of pure bacterial strains to modulate the gastrointestinal microbiome for treating acute graft-versus-host disease (AGVHD) following allogeneic hematopoietic cell transplantation. The research addresses...
- The National Heart, Lung, and Blood Institute awarded $1,577,069 to the Regents of the University of Minnesota on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel therapies for chronic graft-versus-host disease fibrosis using murine models and state-of-the-art molecular techniques. The award funds research into the pathobiology of chronic graft-versus-host disease (CGVHD), specifically investigating how T cell and B cell engagement initiates disease...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $158,892 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the impact of DNMT3A protein reduction on normal and clonal hematopoiesis. The research investigates mechanisms by which somatic DNMT3A mutations drive clonal hematopoiesis—the clonal expansion of mutated hematopoietic stem and progenitor cells—which accelerates with age and increases the risk of hematologic...
- The National Heart, Lung, and Blood Institute awarded The Medical College of Wisconsin, Inc. $675,405 on June 15, 2026, under CFDA 93.837 (Cardiovascular Diseases Research) to conduct research on augmenting regulatory T cell reconstitution during graft versus host disease (GVHD). The project runs through April 30, 2030, with work performed in Wauwatosa, Wisconsin. The research addresses GVHD, the major complication of allogeneic hematopoietic stem cell transplantation, by examining the...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $643,349 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 17, 2026, to investigate the role of gasdermin D (GSDMD) inhibition in reducing inflammation-related atrial fibrillation risk associated with clonal hematopoiesis and aging. The research employs bone marrow transplantation, deep cardiac phenotyping, single-cell transcriptomics, and genetic analyses to elucidate how clonal...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Trustees of Boston University $100,228 on December 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate enhancement of engraftment potential in human hematopoietic stem cells. The research addresses the challenge of preserving hematopoietic stem cell functionality during the ex vivo culture steps required for gene editing therapies. The project employs multi-modal profiling of...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $825,533 for Project Grant R01HL182745 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project investigates glycorna-based control of angiogenesis through heparan sulfate binding growth factors. Research focuses on how vascular endothelial growth factor (VEGF-A) orchestrates vascular and cardiac development by binding...